EU Ombudsman Asks EMA to Improve Transparency

The European Medicines Agency (EMA) should review a 2008 citizen request for information on adverse drug reactions associated with a popular acne drug and take steps to make the reports publicly available, EU Ombudsman Nikiforos Diamandouros says in a draft recommendation. The agency also should consider possibilities for providing public access to the requested reports in any form, including electronic, he adds.
International Pharmaceutical Regulatory Monitor